Please assess the completion status of the following clinical trial:

Trial Title: The Confirmatory Olmesartan Plaque Regression Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female Caucasian outpatients aged \> 40 years.~* High BP defined as mean SeSBP/SeDBP ≥ 140/90 mmHg.~* One or more of the following additional risk factors:~* Smoking;~* Dyslipidaemia (high-density lipoprotein (HDL)-cholesterol \< 0.9 mmol/L or low-density lipoprotein (LDL)-cholesterol \> 2.6 mmol/L, or triglycerides \> 1.7 mmol/L);~* Left ventricular hypertrophy;~* Cardio-cerebrovascular events \> 6 months ago;~* Presence of target organ damage.~* Non-calcified (not marked shadowing) plaque in the CC artery, in the internal carotid artery or the carotid bulb with a PV ≥ 0.040 cm³ (≥ 40 µL) according to the measurements of EUTARC.~Exclusion Criteria:~* Secondary or high grade hypertension including grade III hypertension (SeSBP of \> 180 mmHg or SeDBP of \> 105 mmHg).~* Stroke, myocardial infarction within the previous 6 months.~* Interventional or surgical vascular treatment within the previous 3 months.~* Presence of significant narrowing of the aortic or bicuspid valve and severe obstruction of cardiac outflow (hypertrophic cardiomyopathy).~* Symptomatic heart failure.~* Diabetes.~* Chronic obstructive pulmonary disease (COPD) or asthma.~* Claudication intermittens stage II b or higher.~* Clinical evidence of severe renal disease \[including renovascular occlusive disease, nephrectomy and/or renal transplant, creatinine clearance of \< 30 mL/min, macroalbuminuria (\> 300 mg albumin/24 hours or 300 µg albumin/mg creatinine)\].~* Treatment with angiotensin converting enzyme (ACE)-inhibitors or angiotensin-receptor blockers (ARBs) during last 3 months.~* Start of treatment with a lipid-lowering agent or modification of dosage within last 3 months.~* Electrocardiographic (ECG) evidence of 2nd or 3rd degree atrioventricular (AV) block, atrial fibrillation, cardiac arrhythmia (requiring therapy) or bradycardia (\< 50 beats/min at rest).~* Known intolerance to study drugs.~* Impaired liver function tests suggesting severe liver disorder.~* Any life threatening disease.~* Duplex sonographically determined stenosis of the common or internal carotid artery \> 75%.~* Plaque with marked shadowing from calcification.~* Target plaques in CC artery extending into both internal and external arteries.~* Pregnant or lactating female subjects.~* Female subjects of childbearing potential without adequate contraception: intra-uterine devices, hormonal contraceptives, either oral, depot, patch or injectable and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. If a female becomes pregnant during the trial, she has to be withdrawn immediately (see section 9.4).~* Subject is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents.~* Subject has previously entered this study.~* Subjects who have received ATE within 30 days prior to entering the active treatment phase.~* Subjects who are unwilling or unable to provide informed consent or to participate satisfactorily for the entire trial period.~* Subjects with history of alcohol and or drug abuse.~* Subjects with known malabsorption syndrome.~* Subjects who had donated or lost 450 mL or more blood during the last three months before Screening.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
- Olmesartan medoxomil (Type: EXPERIMENTAL): Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).